GoodRx Holdings, Inc.
HealthcareNASDAQ:GDRX · NASDAQ Global Select
+$0.02 today
Vol 0.67M · Avg 1.63M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
4.9%
avg -15.8%
ROIC
4.0%
avg 5.7%
ROA
2.2%
avg 1.1%
Analysis
ROE is currently the strongest return metric at 4.9% versus its period average of -15.8%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Wendy Barnes | President, Chief Executive Officer & Director | $3.45M | — | 53 | $1.27M | 0.37% |
Christopher A. McGinnis | Chief Financial Officer & Treasurer | $1.72M | — | 55 | $492,580.00 | 0.14% |
Ryan Sullivan | Chief Marketing Officer | $864,801.00 | — | — | — | — |
Romin Nabiey | Executive Officer | $501,951.00 | — | 39 | $185,949.00 | 0.05% |
Douglas Joseph Hirsch | Co-founder & Director | $30,000.00 | — | 55 | $247,502.00 | 0.07% |
Vina Leite | Chief People Officer | — | — | 56 | — | — |
Scott Paul | Senior Vice President of Healthcare & Consumer Innovation | — | — | — | $216,663.00 | 0.06% |
Aubrey Reynolds | Director of Investor Relations | — | — | — | — | — |
Thomas Chan | Chief Accounting Officer & Principal Accounting | — | — | 40 | $29,003.00 | <0.01% |
Gracye Cheng | Senior Vice President, General Counsel & Secretary | — | — | — | — | — |
Justin Fengler | Chief Strategy & Operations Officer | — | — | — | — | — |
Nitin Shingate | Chief Technology Officer | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
3
$76,130.24
Net Sentiment
$76,130.24
Net selling
Most Active
Spectrum Equity VII, L.P.
3 transactions
Analysis
Insiders reported 0 buys worth $0.00 and 3 sells worth $76,130.24 over the last 12 months. That adds up to net selling of $76,130.24. Spectrum Equity VII, L.P. was the most active insider with 3 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A5 analysts |
| Revenue | N/A | N/A | +51.9% | +6.2% (10yr)5 analysts |
| Net Income | N/A | N/A | N/A | N/A5 analysts |
| EBIT | N/A | N/A | N/A | N/A5 analysts |
Analysis
Recent growth has been strongest in Revenue at +51.9% over three years. Forward estimates point to Revenue at +6.2% (10yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Pulse Biosciences, Inc.
NASDAQ:PLSE
$1.69B
Innoviva, Inc.
NASDAQ:INVA
$1.68B
AdaptHealth Corp.
NASDAQ:AHCO
$1.38B
IRadimed Corporation
NASDAQ:IRMD
$1.20B
Collegium Pharmaceutical, Inc.
NASDAQ:COLL
$1.12B
Amphastar Pharmaceuticals, Inc.
NASDAQ:AMPH
$885.83M
HealthStream, Inc.
NASDAQ:HSTM
$763.39M
MiMedx Group, Inc.
NASDAQ:MDXG
$536.20M
Claritev Corporation
NYSE:CTEV
$526.61M
LifeMD, Inc.
NASDAQ:LFMD
$227.30M
Who manages GDRX?
GoodRx Holdings, Inc. (GDRX) lists 12 active executives. The top listed executive is Vina Leite, Chief People Officer.
Are GDRX insiders buying or selling?
Recent insider activity shows net buying of $457.80T.
Explore More
Continue the stock analysis
Jump to another research area for this company.